Linifanib Fails to Meet Overall Survival Endpoint for Advanced Hepatocellular Carcinoma
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, linifanib and sorafenib had similar overall survival for the treatment of patients with advanced hepatocellular carcinoma (HCC), while sorafenib was more safe.
For the open-label phase 3 study, researchers enrolled 1,035 patients with a median age of 60 years old with advanced HCC and randomly assigned them to receive linifanib 17.5mg orally once daily or sorafenib 400mg orally twice daily.
Linifanib is a novel, potent tyrosine kinase inhibitor currently under development by Abbott Laboratories. Of those enrolled, 66.6% were Asian, 65.2% had an ECOG performance score of 0, 49.1% had hepatitis B infection, and 70.1% had vascular invasion or extrahepatic spread.
Results showed a median overall survival of 9.1 months (95% CI: 8.1 - 10.2) with linifanib and 9.8 months (95% CI: 8.3 - 11.0; HR = 1.046; 95% CI: 0.896 - 1.221) with sorafenib. The median time to progression was found to be 5.4 months (95% CI: 4.2 - 5.6) and 4.0 months (95% CI: 2.8 - 4.2: HR = 0.759; 95% CI: 0.643 - 0.895; P = 0.001).
In addition, objective response rates were 13.0% in the linifanib group and 6.9% in the sorafenib group. In regard to safety, serious adverse effects were more common in the linifanib arm and were more likely to cause discontinuation and dose modification (P < 0.001).
Linifanib and sorafenib had similar overall survival for the treatment of advanced HCC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed